Method for separating and purifying mRNA (messenger ribonucleic acid)
By using affinity chromatography medium 6FF-BVS-Odt-Cys and an automated chromatography system, the problem of low purity and selectivity in mRNA purification is solved, and efficient and simple mRNA isolation and purification is achieved, suitable for a variety of RNA samples, improving the Purity and separation efficiency are reduced, and operational complexity and cost are reduced.
Patent Information
- Application Number
- CN202411362926.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-27
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2044-09-27
AI Technical Summary
The existing mRNA purification methods have problems such as low purity, low selectivity, high cost and complex operation, making it difficult to achieve efficient and simple mRNA isolation and purification.
Using affinity chromatography medium 6FF-BVS-Odt-Cys, the oligonucleotide probe oligo (dT) is linked by agarose gel and bis(vinylsulfone)methane, and bound to cysteine blocking for specific mRNA with poly(A) tail is captured sexually and gradient elution is performed using an automated chromatography system to achieve high purity and high yield purification of mRNA.
It improves the purity and separation efficiency of mRNA, reduces operational complexity and cost, and is suitable for a variety of RNA samples, ensuring the repeatability of experimental results.
Smart Images

Figure CN118956858A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biotechnology, and in particular relates to a method for separating and purifying mRNA. Background Art
[0002] As an important biological molecule, mRNA (messenger ribonucleic acid) plays a bridging role in transcribing genetic information from DNA to protein in cells. In recent years, mRNA technology has shown great application potential in vaccine development, gene therapy and other fields. With the rapid development of mRNA vaccine technology, higher requirements are placed on mRNA purification technology. Traditional mRNA purification methods, such as lithium chloride precipitation, size exclusion chromatography, ion exchange HPLC and reversed-phase ion pairing HPLC, have problems of low purity and low selectivity. The highly selective and specific mRNA purification method mainly uses oligo(dT) as a ligand for mRNA affinity chromatography. However, the previously reported methods for preparing oligo(dT) affinity chromatography media all have certain disadvantages. For example, when streptavidin is used to connect oligo(dT), the oligo(dT) density of the affinity chromatography medium is low due to steric hindrance, so only a small amount of mRNA can be separated and extracted; when CDI is used as a coupling agent, the reaction efficiency of the 5' and 3' amino groups with CDI is low, and the connected oligo(dT) is only 20% of the oligo(dT) raw material, which increases the consumption of raw materials and thus increases the production cost of the affinity chromatography medium; when ethylene oxide is used as the active group of the affinity chromatography medium to react with the 5' and 3' amino groups of oligo(dT), there is a problem of low reaction activity, and the reaction needs to be carried out at high temperature or pH>9. In addition, it is difficult to obtain relatively pure mRNA through one-step purification, and multiple methods need to be combined. Multi-step chromatography is often used to purify and separate mRNA, which has high technical requirements for operators. The above disadvantages are not conducive to the production and industrial application of affinity chromatography media. Therefore, it is very important to develop an efficient, simple to operate, high-purity mRNA separation and purification method for the application of mRNA. Summary of the invention
[0003] In order to solve the problems existing in the background technology, the purpose of the present invention is to provide a method for separating and purifying mRNA, which can solve the problems of low mRNA purification efficiency, high cost and complex operation in the prior art, and the process can achieve high-purity and high-yield purification of mRNA.
[0004] In order to achieve the above object, the present invention provides the following technical solutions:
[0005] The present invention provides a method for separating and purifying mRNA, comprising the following steps:
[0006] (1) Sample preparation: extract the nucleic acid sample to be separated and adjust it to a concentration suitable for purification;
[0007] (2) Affinity chromatography medium selection: Select appropriate affinity chromatography medium based on the characteristics of the target mRNA;
[0008] (3) Buffer preparation: Prepare a salt-containing buffer and adjust the pH and salt concentration according to the type of nucleic acid;
[0009] (4) Chromatographic system setting: loading the affinity chromatography medium obtained in step (2) into the chromatographic column and selecting elution conditions;
[0010] (5) Sample loading: the nucleic acid sample obtained in step (1) is dissolved in an injection solution and then loaded into a chromatographic column, and the mRNA is captured using an affinity chromatography medium;
[0011] (6) Elution and collection: Pump in the elution buffer for step-by-step gradient elution and collect the purified mRNA.
[0012] In the technical solution described above, preferably, the nucleic acid sample to be separated in step (1) includes but is not limited to using an RNA extraction reagent, and obtaining a total RNA sample by centrifugation and precipitation separation; or using in vitro transcription (IVT) technology, using a specific DNA template and RNA polymerase, adding a poly (A) tail with a length of 1-80 nt to synthesize the target RNA sample.
[0013] In the technical solution described above, preferably, the RNA extraction reagent includes Trizol reagent.
[0014] For the technical solution described above, preferably, the method of using Trizol reagent to lyse cells and extract RNA includes the following steps: 1) first wash the cells with PBS and centrifuge to precipitate the cells, add Trizol reagent, and repeatedly blow or shake violently to lyse the cells; 2) extract with chloroform, isopropanol, and ethanol in sequence to obtain the RNA sample to be separated.
[0015] For the technical solution described above, preferably, the method for synthesizing mRNA by in vitro transcription (IVT) technology includes the following steps: 1) providing a DNA template containing a specific gene sequence; 2) adding RNA polymerase (such as T7, SP6 or T3 RNA polymerase) and other necessary transcription factors; 3) in a suitable buffer system and conditions, the RNA polymerase catalyzes the transcription of the DNA template into an RNA molecule; 4) purifying the obtained RNA product and adding a poly (A) tail with a length of 0-80 nt for subsequent separation and purification experiments.
[0016] In the technical solution described above, preferably, the concentration of the nucleic acid sample to be separated in step (1) is adjusted to 10-900 ng / μL.
[0017] In the technical solution described above, preferably, the affinity chromatography medium described in step (2) includes but is not limited to 6FF-BVS-Odt-Cys, wherein the 6FF-BVS-Odt-Cys is based on agarose gel (6FF) as a matrix, bis(vinylsulfone)methane (BVS) as a connecting arm to connect the oligonucleotide probe oligo(dT), and finally blocked with cysteine. The obtained mRNA affinity chromatography medium is used to specifically capture mRNA with a poly(A) tail.
[0018] In the technical solution described above, preferably, the density of oligo(dT) is 0.05-0.25 μmol / mL.
[0019] In the technical solution described above, preferably, the length of oligo(dT) is 1-80 nt.
[0020] In the technical solution described above, preferably, the salt-containing buffer described in step (3) is a phosphate buffer, a Tris buffer or a buffer system suitable for nucleic acid stabilization.
[0021] In the technical solution described above, preferably, the type of salt in the buffer solution is one or a combination of two or more of sodium chloride, sodium sulfate, sodium oxalate, sodium acetate, sodium citrate, and ammonium sulfate.
[0022] In the technical solution described above, preferably, the salt concentration in the salt-containing buffer is 0.01M-1.0M.
[0023] In the technical solution described above, preferably, the pH value of the buffer solution is in the range of 6.8-7.4.
[0024] In the technical solution described above, preferably, the chromatographic system described in step (4) is selected For the purifier 10 system, select UNICORN software for automatic control to set the chromatography system parameters.
[0025] In the technical solution described above, preferably, before the nucleic acid sample is loaded in step (5), the chromatographic system is washed and balanced using a washing solution and a balancing solution in sequence, wherein the washing solution is ultrapure water, and the washing volume is 5-25 column volumes, and the balancing solution is a salt-containing buffer, and the balancing volume is 25-50 column volumes.
[0026] In the technical solution described above, preferably, the loading of the nucleic acid sample to be separated is completed by an automatic sample injector or a manual syringe.
[0027] In the technical solution described above, preferably, the concentration of the nucleic acid sample in the injection solution is 1-50 μg / mL or 5-10 nmol / mL.
[0028] For the technical solution described above, preferably, the injection liquid is a lithium chloride solution and a salt-containing buffer prepared in step 3) in a volume ratio of 1:1-1:20, and the synergistic effect promotes the binding of mRNA to the affinity chromatography medium. Preferably, the concentration of the lithium chloride solution is 0.5-5M.
[0029] For the technical solution described above, in preferred cases, the flow rate of the injection process is controlled within a range suitable for chromatography, which is 0.2-1.0 mL / min; in preferred cases, the flow rate is first controlled at 0.8-1.0 mL / min, and rapid injection allows the mRNA in the sample to quickly bind to the oligo(dT) probe in the affinity chromatography medium, and then the flow rate is adjusted to 0.2-0.5 mL / min to allow all unbound oligo(dT) probes to bind.
[0030] In the technical solution described above, preferably, the gradient elution described in step (6) is a step-by-step concentration gradient elution, specifically, eluting with 0.5M NaCl aqueous solution for 5 min, eluting with 0.1M NaCl aqueous solution for 5 min, and eluting with ultrapure water for 5 min, respectively, with the flow rate controlled at 0.2-0.5mL / min, the pressure at 0.01-0.3MPa, and the temperature at room temperature. When an absorption peak is detected at an ultraviolet absorption wavelength of 260nm, mRNA is collected until the absorption peak returns to the baseline and collection is stopped.
[0031] Compared with the prior art, the mRNA separation and purification method of the present invention has the following beneficial effects:
[0032] (1) High purity: Affinity chromatography technology can effectively remove impurities in the sample and improve the purity of mRNA.
[0033] (2) High efficiency: using automation The purifier 10 system reduces manual operations and improves separation efficiency.
[0034] (3) Repeatability: The repeatability of experimental results is ensured through standardized operating procedures and parameter settings.
[0035] (4) Wide application: Applicable to RNA samples from various sources, including total RNA in cell lysates and crude IVT products. BRIEF DESCRIPTION OF THE DRAWINGS
[0036] In order to more clearly illustrate the embodiments of the present invention, the drawings related to the embodiments are briefly introduced below.
[0037] Figure 1 Schematic diagram of extracting mRNA from total RNA;
[0038] Figure 2 Capillary electrophoresis diagrams of IVT products before (A) and after (B) purification using oligo(dT) affinity chromatography media. DETAILED DESCRIPTION
[0039] The present invention is described in detail below with reference to the embodiments, but the embodiments of the present invention are not limited thereto. Obviously, the embodiments described below are only partial embodiments of the present invention. For those skilled in the art, other similar embodiments obtained without creative labor all fall within the protection scope of the present invention.
[0040] Example 1
[0041] This example provides a method for extracting total RNA samples from cell lysate, and the preparation method is as follows:
[0042] 1. Prepare 0.01 M PBS (pH = 7.4) buffer.
[0043] 2. Transfer the human pancreatic cancer cells SW1990 cultured in a T75 culture flask into a centrifuge tube, wash twice with 0.01M PBS (pH=7.4) and then dry. Mix 1ml Trizol reagent with 1ml 0.01M PBS buffer, add to the cells and mix well, and let stand on ice for 5 minutes. Centrifuge the cells at 4°C, 12000rpm for 15 minutes, and use a pipette to aspirate the upper water layer to obtain cell lysate.
[0044] 3. Add 200μl chloroform, let stand on ice for 5min, and centrifuge at 4℃, 12000rpm for 10min. Pipette the upper aqueous phase into another centrifuge tube, add 200μL isopropanol and mix well, let stand on ice for 10min, and centrifuge at 4℃, 12000rpm for 10min. Remove the supernatant, add 1ml 75% ethanol, and centrifuge at 4℃, 12000rpm for 5min. Remove the supernatant, dry, and add 20μl sterile enzyme-free water to dissolve the precipitate to obtain total RNA.
[0045] Total RNA samples were measured using Nano Drop 2000. 260 / A 280=1.88, that is, the total RNA concentration is 3426.6 ng / μL, which proves that total RNA samples can be extracted from cell lysate for further separation and purification of mRNA.
[0046] Example 2
[0047] This embodiment provides a preparation of an mRNA in vitro transcription system, and the preparation method is as follows:
[0048] Firefly fluorescent protease mRNA was selected as a template, and the firefly fluorescent protease DNA obtained by enzyme linearization was transcribed in vitro using a High Yield T7 RNA Synthesis Kit to obtain a crude in vitro transcription (IVT) product.
[0049] The nucleotide sequence of firefly fluorescent protease mRNA is as follows:
[0050] >T7 promoter
[0051] TAATACGACTCACTATA+AGG
[0052] >5'UTR-Pfizer-V1 truncated
[0053] TAGTATTCTTCTGGTCCCCACAGACTCAGAGAGAACCCGCCACC
[0054] >Luciferase (ORF optimization)
[0055]
[0056] >3'UTR-Pfizer
[0057] CTCGAGCTGGTACTGCATGCACGCAATGCTAGCTGCCCCTTTCCCGTCCTGGGTACCCCGAGTCTCCCCGACCTCGGGTCCCAGGTATGCTCCCACCTCCACCTGCCCCACTCACCACCTCTGCTAGTTCCAGACACCTCCCAAGCACG CAGCAATGCAGCTCAAAACGCTTAGCCTAGCCACACCCCCACGGGAAACAGCAGTGATTAACCTTTAGCAATAAACGAAAGTTTAACTAAGCTATACTAACCCCAGGGTTGGTCAATTTCGTGCCAGCCACACCCTGGAGCTAGC
[0058] >polyA tail (80)
[0059] AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
[0060] >Restriction site
[0061] AGAAGAGC.
[0062] Example 3
[0063] This embodiment provides a method for separating and purifying mRNA, which comprises the following steps:
[0064] 1. Preparation of affinity chromatography medium 6FF-BVS-Odt-Cys (reference CN117123201A), the preparation method is: using agarose gel (6FF) as a matrix and bis(vinylsulfone)methane (BVS) as a linker, in a salt-containing coupling buffer at pH 7, reacting an oligonucleotide probe Oligo(dT) (length 50 nt) that is not pre-modified at the 5' end and 3' end with a vinyl sulfone functionalized agarose gel matrix for 24 hours, and finally blocking the excess BVS with a blocking reagent cysteine (Cys). The obtained mRNA affinity chromatography medium 6FF-BVS-OdT-Cys is used to specifically capture mRNA with a poly(A) tail, and the final Oligo(dT) density is 0.25 μmol / mL. The prepared affinity chromatography medium 6FF-BVS-OdT-Cys is soaked in 20% ethanol for standby use.
[0065] 2. Use 0.1% DEPC to treat centrifuge tubes, buffer solutions and other experimental supplies to remove RNase, and then rinse with enzyme-free water.
[0066] 3. Dilute the total RNA sample in the lysate of human pancreatic cancer cell SW1990 to 100 μl, add 100 μl 100mM PBS buffer (1.0M NaCl, pH=7) to it, mix well, and add to the affinity chromatography medium 6FF-BVS-Odt-Cys, shake at 4°C, 750rpm for 15min. After the reaction, wash the affinity chromatography medium with sterile enzyme-free water and buffer (5mL 1M lithium chloride solution, 10mL PBS buffer), and elute the bound mRNA with 100 μl 0.5M NaCl, 100 μl 0.1M NaCl, and 100 μl ultrapure water in a stepwise concentration gradient. Use Nano Drop 2000 to measure the eluate in the centrifuge tube. The content of mRNA in the eluate is about 3% of the total RNA, which confirms that the prepared affinity chromatography medium can be used to purify mRNA in the RNA sample to be tested.
[0067] Example 4
[0068] This embodiment provides a method for separating and purifying mRNA using The Purifier 10 system uses affinity chromatography medium 6FF-BVS-OdT-Cys to separate and purify mRNA from crude IVT transcription products, including the following steps:
[0069] 1. Load 0.1 mL of the above affinity chromatography medium 6FF-BVS-OdT-Cys into a NaVALID Pro medium-pressure chromatography column, where the oligo(dT) density is 0.25 μmol / mL.
[0070] 2. Wash the chromatography system with 25 CV of ultrapure water and equilibrate the chromatography column with 50 CV of buffer (50 mM PBS buffer, 1.0 M NaCl, 1 mM EDTA, pH 7.0).
[0071] 3. The nucleic acid sample to be separated is firefly luciferase mRNA, which consists of 2103 nucleotides (nt), including an 80nt poly(A) tail added by co-transcription. Then, the sample solution (5mL 1M lithium chloride solution, 10mL buffer) with a nucleic acid sample concentration of 10nmol / mL was pumped into the sample solution at flow rates of 0.2, 0.6, 1.0, and 5.0mL / min, respectively. Purifier 10 system, 0.5M NaCl, 0.1M NaCl, ultrapure water were used to elute the bound mRNA step by step, and then the chromatography column was cleaned online with 0.1M NaOH. The mRNA components were collected and the content was determined. The affinity chromatography medium had an mRNA loading capacity of 1.07, 1.05, 1.02, and 0.63 mg / mL at flow rates of 0.2, 0.6, 1.0, and 5.0 mL / min. It was proved that the affinity chromatography medium can effectively purify mRNA containing poly (A) at a flow rate of 0.2-5.0 mL / min.
[0072] Example 5
[0073] This embodiment provides a method for separating and purifying mRNA using The Purifier 10 system uses affinity chromatography medium 6FF-BVS-OdT-Cys to separate and purify mRNA from crude IVT transcription products, including the following steps:
[0074] 1. Load 0.1 mL of the above affinity chromatography medium 6FF-BVS-OdT-Cys into a NaVALID Pro medium-pressure chromatography column, where the oligo(dT) density is 0.25 μmol / mL.
[0075] 2. Wash the chromatographic system with 5CV of ultrapure water and equilibrate the chromatographic column with 25CV of buffer (50mM Tris buffer, 0.1MNa2SO4, pH 7.4).
[0076] 3. The nucleic acid sample to be separated is firefly luciferase mRNA, which consists of 2103 nucleotides (nt) and includes an 80nt poly(A) tail added by co-transcription. Then, the sample solution (5mL 1M lithium chloride solution, 10mL buffer) with a nucleic acid sample concentration of 50μg / mL is pumped into the Purifier 10 system, and then adjust the system flow rate to 0.2mL / min. After 10min, 0.5M NaCl, 0.1M NaCl, and ultrapure water were used to elute the bound mRNA step by step, and then 0.1M NaOH was used to clean the chromatography column online. The mRNA components were collected and the content was determined. The mRNA loading capacity of the affinity chromatography medium was 4.05mg / mL.
[0077] Example 6
[0078] This embodiment provides a method for separating and purifying mRNA using The Purifier 10 system uses affinity chromatography medium 6FF-BVS-OdT-Cys to separate and purify mRNA from crude IVT transcription products, including the following steps:
[0079] 1. Load 0.1 mL of the above affinity chromatography medium 6FF-BVS-OdT-Cys into a NaVALID Pro medium-pressure chromatography column, wherein the oligo(dT) density is 0.05 μmol / mL.
[0080] 2. Wash the chromatography system with 10 CV of ultrapure water and equilibrate the chromatography column with 30 CV of buffer (50 mM PBS buffer, 1.0 M NaCl, 1 M EDTA, pH 6.8).
[0081] 3. The nucleic acid sample to be separated is firefly luciferase mRNA, which consists of 2103 nucleotides (nt), including an 80nt poly(A) tail added by co-transcription. Then, the sample solution (5mL 1M lithium chloride solution, 10mL buffer) with a nucleic acid sample concentration of 10nmol / mL is pumped into the purifier 10 system, and then change the system flow rate to 0.5mL / min. After 10 minutes, the bound mRNA was eluted with 0.5M NaCl, 0.1M NaCl, and ultrapure water in a step-by-step concentration gradient, and then the chromatography column was cleaned online with 0.1M NaOH. The mRNA components were collected and the content was determined. The mRNA loading capacity of the affinity chromatography medium was 3.03mg / mL.
[0082] Example 7
[0083] This embodiment provides a method for separating and purifying mRNA using The Purifier 10 system uses affinity chromatography medium 6FF-BVS-OdT-Cys to separate and purify mRNA from crude IVT transcription products, including the following steps:
[0084] 1. Load 0.1 mL of the above affinity chromatography medium 6FF-BVS-OdT-Cys into a NaVALID Pro medium-pressure chromatography column, where the oligo(dT) density is 0.10 μmol / mL.
[0085] 2. Wash the chromatography system with 20 CV of ultrapure water and equilibrate the chromatography column with 50 CV of buffer (50 mM PBS buffer, 1 M NaCl, 1 mM EDTA, pH 7.0).
[0086] 3. The nucleic acid sample to be separated is a total RNA sample obtained after cell lysis, containing a variety of mRNAs. Then, a buffer solution (10 mM Tris buffer, 1.0 M NaCl, 1 mM EDTA, pH 7.0) with a nucleic acid sample concentration of 20 μg / mL is pumped into the Purifier 10 system, after 10 minutes, 0.5M NaCl, 0.1M NaCl, and ultrapure water were used to elute the bound mRNA step by step, and then the chromatography column was cleaned online with 0.1M NaOH. The mRNA components were collected and the content was determined. The mRNA loading capacity of the affinity chromatography medium was 1.20mg / mL.
[0087] Example 8
[0088] The crude IVT transcription product of firefly fluorescent protease mRNA and the firefly fluorescent protease mRNA eluate purified by the affinity chromatography medium prepared in Example 4 were analyzed by capillary electrophoresis. The experimental results are as follows: Figure 2 The figure shows that the main peak position detected in the eluate obtained after purification by affinity chromatography medium is basically consistent with that before purification, and the impurity peaks are significantly reduced, proving that the desired mRNA has been purified.
Claims
1. A method for separating and purifying mRNA, characterized in that: The following steps are involved: (1) Sample preparation: extract the nucleic acid sample to be separated and adjust it to a concentration suitable for purification; (2) Affinity chromatography medium selection: Select appropriate affinity chromatography medium based on the characteristics of the target mRNA; (3) Buffer preparation: Prepare a salt-containing buffer and adjust the pH and salt concentration according to the type of nucleic acid; (4) Chromatographic system setting: loading the affinity chromatography medium obtained in step (2) into the chromatographic column and selecting elution conditions; (5) Sample loading: the nucleic acid sample obtained in step (1) is dissolved in an injection solution and then loaded into a chromatographic column, and the mRNA is captured using an affinity chromatography medium; (6) Elution and collection: Pump in the elution buffer for step-by-step gradient elution and collect the purified mRNA.
2. The method according to claim 1, characterized in that The nucleic acid sample to be separated in step (1) includes, but is not limited to, using an RNA extraction reagent, and separating the total RNA sample by centrifugation and precipitation; or using in vitro transcription (IVT) technology, using a specific DNA template and RNA polymerase, adding a poly (A) tail with a length of 1-80 nt to synthesize the target RNA sample; the concentration of the nucleic acid sample to be separated is adjusted to 10-900 ng / μL.
3. The method according to claim 1, characterized in that: The affinity chromatography medium described in step (2) includes but is not limited to 6FF-BVS-Odt-Cys, wherein the 6FF-BVS-Odt-Cys is based on agarose gel (6FF) as a matrix, bis(vinylsulfone)methane (BVS) as a connecting arm to connect the oligonucleotide probe oligo(dT), and finally blocked with cysteine to obtain an mRNA affinity chromatography medium; the oligo(dT) density in the affinity chromatography medium is 0.05-0.25 μmol / mL.
4. The method according to claim 1, characterized in that: The salt-containing buffer described in step (3) includes but is not limited to phosphate buffer, Tris buffer or a buffer system suitable for nucleic acid stabilization; the type of salt in the buffer is one or a combination of two or more of sodium chloride, sodium sulfate, sodium oxalate, sodium acetate, sodium citrate, and ammonium sulfate; the salt concentration in the salt-containing buffer is 0.01M-1.0M; and the pH value range of the buffer is 6.8-7.
4.
5. The method according to claim 1, characterized in that The chromatographic system selected in step (4) Purifier 10 system, the automatic control software selects UNICORN software to set the flow rate, pressure and temperature parameters of the chromatographic column in the chromatography system.
6. The method according to claim 1, characterized in that Before loading the nucleic acid sample in step (5), the chromatographic system is washed and balanced with a washing solution and a balancing solution in sequence, wherein the washing solution is ultrapure water, and the washing volume is 5-25 column volumes, and the balancing solution is a salt-containing buffer, and the balancing volume is 25-50 column volumes.
7. The method according to claim 1, characterized in that In step (5), the loading of the nucleic acid sample to be separated is completed by an automatic sample injector or a manual syringe; the concentration of the nucleic acid sample in the injection solution is 1-50 μg / mL or 5-10 nmol / mL.
8. The method according to claim 7, characterized in that The injection solution is a lithium chloride solution and a salt-containing buffer prepared in step 3) in a volume ratio of 1:1-1:20, which synergistically promotes the binding of mRNA to the affinity chromatography medium. The concentration of the lithium chloride solution is 0.5-5M.
9. The method according to claim 1, characterized in that: The flow rate of the injection process in step (5) is controlled at 0.2-1.0 mL / min; first, the flow rate is controlled at 0.8-1.0 mL / min, and the rapid injection allows the mRNA in the sample to quickly bind to the oligo(dT) probe in the affinity chromatography medium, and then the flow rate is adjusted to 0.2-0.5 mL / min to allow all unbound oligo(dT) probes to bind.
10. The method according to claim 1, characterized in that The gradient elution described in step (6) is specifically to use 0.5M NaCl aqueous solution, 0.1M NaCl aqueous solution, and ultrapure water for stepwise concentration gradient elution, respectively, with the flow rate controlled at 0.2-0.5mL / min, the pressure at 0.01-0.30MPa, and the temperature at room temperature. When the absorption peak is detected at the ultraviolet absorption wavelength of 260nm, mRNA is collected until the absorption peak returns to the baseline and the collection is stopped.
Citation Information
Patent Citations
Application of chromatographic filler taking Oligo (dT) as affinity ligand
CN114381454A
Oligo-dT affinity chromatography filler and preparation method thereof
CN117123201A
Method for purifying in-vitro transcription mRNA (messenger ribonucleic acid) and application
CN117603958A
Oligo dT magnetic bead reagent for enriching mRNA and use method of Oligo dT magnetic bead reagent
CN118389489A
